Milrinone Infusion for VAsospam Treatment in Subarachnoid hemoRrhage
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
Subarachnoid hemorrhage (SAH) is a frequent and severe disease. Mortality can reach 40%. The
most frequent complication of SAH is arterial vasospasm, with estimated incidence as high as
70%. Vasospasm is responsible for cerebral ischemia leading to severe morbidity, poorer
quality of life and increased mortality.
Intravenous Milrinone, because of vasodilatory properties could be a therapeutic option. We
hypothesize that intravenous infusion of Milrinone will improve the neurological recovery of
patients with vasospasm following aneurysmal SAH at 3 months.
This is a Phase III, multi-center, randomized, double-blinded, placebo-controlled study. The
primary outcome will be the proportion of patients with a good outcome 3 months (defined as a
modified rankin score ≤2).